Catecholamines may influence vascular smooth muscle cell (SMC) growth and vascular hypertrophic diseases. We previously demonstrated that stimulation of ␣ 1 -adrenoceptors (AR) causes hypertrophy of vascular SMCs in vitro and in situ. Here, we used adult rat aorta SMCs that express ␣ 1D -and ␣ 1B -ARs (but not ␣ 1A -ARs) in vitro to examine the mechanisms and ␣ 1 -AR subtypes involved. Norepinephrine (NE) increased protein synthesis and content in a time-and dose-dependent manner. To identify the responsible ␣ 1 -AR subtype, we first documented the selectivity of two ␣ 1 -AR subtype antagonists, BMY 7378 (␣ 1D -AR antagonist) and chloroethylclonidine (CEC; ␣ 1B -AR antagonist), using Rat-1 fibroblasts stably transfected with the three different rodent ␣ 1 -AR cDNAs. NE dose-dependently increased protein synthesis in each cell line. In ␣ 1D fibroblasts, BMY 7378 inhibited growth and protected ␣ 1D -ARs from CEC alkylation while having little blocking or protecting effect on the growth induced by stimulation of fibroblasts that express ␣ 1A -or ␣ 1B -ARs. In rat aorta SMCs, pretreatment with CEC in the presence of BMY 7378 to protect ␣ 1D -ARs had no effect on NE-induced protein synthesis. BMY 7378 inhibited the SMC growth response with a pK b of 8.4. NE caused rapid and transient p42-p44 mitogen-activated protein kinase (MAPK) activation that was ␣ 1D -AR dependent. Furthermore, NE caused tyrosine phosphorylation of multiple cellular proteins, phosphorylation of Raf-1, and stimulation of c-fos mRNA expression in aorta SMCs. The selective MAPK kinase inhibitor PD 98059 inhibited NE-induced protein synthesis and MAPK activation with IC 50 values of 2.3 and 1.6 M, respectively. These data demonstrate that SMC growth induced by NE is mediated by ␣ 1D -ARs that couple to activation of the MAPK cascade.
posed of three subtypes: ␣ 1A , ␣ 1B , and ␣ 1D . The rat thoracic aorta, which we have used as a model of SMC hypertrophy (7) , expresses transcripts and receptors for ␣ 1B -and ␣ 1D -ARs in intact vessel media and primary SMC culture (7, 14) . ␣ 1A -AR mRNA is present in much lower levels in media and is undetectable by RPA when these cells are maintained in early passage cell culture. 1 This indicates that at least in rat aorta cultured SMCs, hypertrophy is mediated by ␣ 1B -or ␣ 1D -ARs or both. Several ␣ 1D -AR antagonists with good selectivity (ϳ100-fold) have been recently described, such as BMY 7378 (order of selectivity: ␣ 1D Ͼ Ͼ ␣ 1A Ͼ ␣ 1B ) (15) . However, other than the irreversible alkylating antagonist, CEC, which has a 5-10-fold higher ␣ 1B -AR selectivity (order of potency: ␣ 1B Ͼ ␣ 1A Ͼ ␣ 1D ), no selective ␣ 1B -AR antagonists are available (16) . Recently, CEC was shown to block ␣ 1 -AR increases in SMC hypertrophy (7) , hyperplasia (17) , and c-fos expression (13) , leading the authors to suggest an ␣ 1B -AR involvement. However, the low selectivity of CEC requires development of strategies and agents not used in these studies to provide a definitive identification of the responsible subtype.
In addition to identification of the ␣-AR subtype signaling SMC hypertrophy, postreceptor mechanisms coupling ␣ 1 -AR stimulation to increased protein synthesis in these cells have not been examined. MAPK, also known as ERK, and associated upstream effectors and downstream targets of MAPK can be activated by numerous growth factors and G proteincoupled receptors (18, 19) . This cascade is a major signal transduction pathway regulating cell growth and differentiation (19) . Agonist-evoked phosphorylation of MAPK at both tyrosine and threonine residues within a conserved TEY motif on the enzyme is believed to cause MAPK to translocate to the nucleus, where it initiates increased protein synthesis by phosphorylation of p90 rsk , p60
TCF , and other proteins involved in the regulation of cell growth (20) . For example, recent evidence indicates that phosphorylation of MAPK is required for transactivation of c-fos, atrial natriuretic peptide, and myosin light chain-2 promoters in phenylephrineinduced hypertrophy of cardiac myocytes (21) . However, the intracellular signals that couple ␣ 1 -AR activation to vascular SMC growth are unclear.
One purpose of the current study was to determine which ␣ 1 -AR subtype mediates increased SMC protein synthesis. To this end, we developed a "protection from alkylation" strategy using CEC and BMY 7378 to distinguish between ␣ 1B -and ␣ 1D -ARs. Second, we sought to examine whether stimulation of the responsible subtype is coupled to activation of the MAPK cascade. For both purposes, we used a well-characterized rat aorta cell culture model of SMC hypertrophy (7) . Our findings demonstrate that NE-stimulated SMC protein synthesis is mediated by the ␣ 1D -AR. We also find that this hypertrophic response requires MEK activation and includes tyrosine phosphorylation of multiple SMC proteins, increased phosphorylation of Raf-1 kinase, rapid and transient activation of MAPK, and induction of c-fos trans-activating proto-oncogene transcription factor.
Experimental Procedures
Cell culture. The methods for culture of rat thoracic aorta SMCs, derived from 200-g male Sprague-Dawley rats, have been described in detail (7) . Rat-1 FBs stably transfected with full-length ␣-AR subtype cDNAs were grown in Dulbecco's modified Eagle's medium with high glucose, 10% fetal bovine serum, 100 units/ml penicillin, 100 g/ml streptomycin, and 250 g/ml G-418 in a humidified atmosphere containing 5% CO 2 /95% air. FBs that express either ␣ 1D -or ␣ 1B -ARs were obtained from D. A. Schwinn (Duke University, Durham, NC), and FBs that express ␣ 1A -ARs were provided by A. S. Goetz and D. L. Saussy (Glaxo-Wellcome, Research Triangle Park, NC). These transfected FBs stably express similar densities (1-3 pM/mg of protein) of ␣ 1 -ARs. Before experiments, SMCs and FBs were growth-arrested for 48 hr in serum-free, defined media 1-2 days after reaching confluence. This media consisted of 50% Dulbecco's modified Eagle's medium, 50% F-12 media supplemented with 2.85 mg/liter insulin, 5 mg/liter transferrin, 35.2 mg/liter ascorbic acid, 6 g/ml selenium, 100 units/ml penicillin, and 100 g/ml streptomycin. SMCs were seeded at 3000-5000/cm 2 and used at passages 4-6. For experiments with Western and Northern blot assays (see below), SMCs were grown to 85-95% confluence and growth arrested for 48 hr. Viable cell number was determined in duplicate by hematocytometry with trypan blue exclusion.
Protein synthesis and content. [ 35 S]Methionine incorporation and BCA (Pierce Chemical, Rockford, IL) assays, performed in duplicate, were used to examine protein synthesis and protein content, respectively. Growth-arrested SMCs received a change of media containing low methionine (2 mg/liter), 100 M ascorbate, 1 M propranolol, and various concentrations of NE in the presence or absence of ␣ 1 -AR antagonists. At 4-6 hr before cell harvest, [ 35 S]methionine (1 Ci/ml, 1000 Ci/mmol; Amersham, Arlington Heights, IL) was added. Cells were washed twice with 4°PBS and lifted with 0.05% trypsin-EDTA, which was then stopped with serum-containing Medium 199. Pelleted cells were lysed with Nonidet P-40. The supernatant was treated with TCA at a final concentration of 10% in the presence of 100 g/ml bovine serum albumen and incubated for 30 min at 4°. TCA-precipitable counts were collected on GF/C filters (Whatman, Clifton, NJ) and counted in Ecoscint H (National Diagnostics, Atlanta, GA). SMCs were pretreated with antagonists for 30 min before the addition of NE (except for specific ␣-AR antagonist protocol; see below). Total soluble protein was determined using a modified BCA assay (7) .
␣-AR antagonist protocols. ␣ 1 -AR stimulation was achieved with NE in the presence of 100 M ascorbate and 1 M propranolol. The blockade of ␣ 2 -ARs was not included because preliminary experiments showed that increases in protein content were similar in the absence of rauwolscine and in our previous study (7) . A recent study also reported an absence of effect of ␣ 2 -or ␤-AR blockade or stimulation on SMC catecholamine hypertrophy (8) . In all experiments, time-matched control cells were exposed to vehicle but not to NE. Cells were incubated with competitive antagonists (or vehicles) 30 min before agonist addition or in experiments in which protection of ␣ 1D -ARs from CEC alkylation was desired. CEC treatment consisted of incubation of 30 M CEC for 30 min at 37°, followed by three washes with warmed PBS and replacement with fresh media.
The apparent equilibrium dissociation constant (K b ) for the ␣ 1D -AR antagonist BMY 7378 was determined for NE-induced protein synthesis during 24 hr of exposure to various NE concentrations). The pK b for BMY 7378 (expressed as pK b ϭ Ϫlog RPA. Total cellular RNA was isolated by acid guanidinum thiocyanate-phenol-chloroform and standard techniques (7) . A 179-bp fragment corresponding to the third intracellular loop of rat ␣ 1A -AR cDNA (667-846 bp) was synthesized by PCR with two primers (5Ј-gaaggatcc GCC AAG AGA GAA AGC CGG-3Ј and 5Ј-gggaattcc GCT TTC TTC TCT CGA GAA-3Ј). The PCR product was subcloned into BamHI/EcoRI sites of pBluescript SK ϩ vector. Identity and orienta-tion of inserts were assessed by restriction enzyme analysis and sequencing. Plasmid DNA containing the fragment was linearized with XbaI. In vitro transcribed [␣-32 P]CTP-labeled cRNAs were produced by standard techniques with T7 RNA polymerase. The cyclophilin gene, which is ubiquitously expressed in mammalian cells and unresponsive to all stimuli we have examined (22) , was used as an internal control for the ␣ 1A -AR RPA. An 165-bp linearized fragment of rat cyclophilin cDNA (Ambion, Austin, TX) was transcribed in vitro with T7 RNA polymerase. The subsequent RPA protocol was performed as previously described in detail (7) . After hybridization and digestion, the hybridized 179-bp fragment of the ␣ 1A mRNA and a 103-bp fragment of the cyclophilin mRNA were protected and resolved on an 8 M urea, 6% polyacrylamide gel. Dried gels were exposed to film (Kodak X-OMAT) with intensifying screens at Ϫ70°f or 12-72 hr.
Western blot analysis. Growth-arrested SMCs treated with ␣ 1 -AR antagonists (same treatment protocol as for protein synthesis measurements) were incubated with or without NE for various times. After incubation, cells were washed twice with ice-cold PBS and lysed in 250 l of modified RIPA buffer consisting of 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 50 mM HEPES, pH 7.5, 1.0 mM sodium orthovanadate, 50 mM NaF, 0.5 mM phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, and 10 g/ml leupeptin. Insoluble material was removed by centrifugation (14,000 rpm for 15 min at 4°), and protein concentration was determined using a modified BCA assay. For gel mobility shift assay of MAPK and Raf-1 or immunoblot analysis of tyrosine-phosphorylated proteins, 30-100 g of cell lysate protein was electrophoresed in 10-15% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. Membranes were blocked for 1 hr at 25°in Tris-buffered saline/Tween 20 containing 5% nonfat dry milk and probed with anti-MAPK rabbit polyclonal antibody (SC-94, Santa Cruz Biochemicals, Santa Cruz, CA), polyclonal or monoclonal Raf-1 antibodies (C-12, Santa Cruz; and R19120, Transduction Laboratories, Lexington, KY, respectively), or monoclonal antiphosphotyrosine antibody (PY-20, Transduction Laboratories). The immunocomplex was detected using horseradish peroxidase-conjugated protein A visualized by the ECL system (Amersham) after intensive washing of the membranes.
Immunocomplex in vitro MAPK assay. Cell lysate protein (300 g; obtained as described above) was incubated with 10 l each of either ERK-1 (C-16) and ERK-2 (C-14) antiserum (Santa Cruz) and 20 l of 50% (w/v) protein A-Sepharose beads for 4 hr at 4°. The immunoprecipitates were washed three times with lysis buffer and once with MAPK assay buffer (50 mM ␤-glycerophosphate, 1.5 mM EGTA, 0.1 mM sodium orthovanadate, 1.0 mM dithiothreitol, 10 M calmidazolium, 10 mM MgCl 2 , 10 g/ml leupeptin, 10 g/ml aprotinin, 1.0 mM benzamidine). MAPK activity was assayed by resuspending the beads in a total volume of 50 l of MAPK assay buffer containing 0.5 mg/ml myelin basic protein, 50 M ATP, and 3 Ci of [␥-32 P]ATP (6000 Ci/mmol). Reactions were initiated with the addition of ATP, incubated at 30°for 20 min, and stopped by the addition of cold 20% TCA. Samples (50 l) were spotted onto P-81 phosphocellulose filters (Whatman) and washed in 0.5% phosphoric acid four times. The filters were then dried, and the radioactivity that was incorporated into myelin basic protein was determined by liquid scintillation counting.
Northern blot analysis. Equal amounts of total RNA (10 g) were denatured and resolved by electrophoresis in a 1.2% agarose gel containing 1.8% formaldehyde. RNA was transferred to Hybond N (Amersham) nylon membrane. The 1.2-kb SstI/EcoRI fragment of mouse c-fos cDNA and a full-length rat GAPDH cDNA probe (GIBCO BRL, Gaithersburg, MD) were labeled with [␣- 32 P]dCTP using a random labeling method according to the manufacturer's instructions. After UV cross-linking of the RNA, the blot was prehybridized in buffer [5ϫ SSC (1ϫ SSC ϭ 150 mM NaCl, 15 mM sodium citrate), 0.1% SDS, 5ϫ Denhardt's solution (1ϫ Denhardt's ϭ 0.02% Ficol 400, 0.02% polyvinylpyrolidone, and 0.02% bovine serum albumen), 5% formamide, and 50 g/ml herring sperm DNA] at 42°for 4 hr and then hybridized in the same buffer with probe (2 ϫ 10 6 cpm/ml) overnight at 42°. The blot was washed with 2ϫ SSC/0.2% SDS twice at room temperature for 10 min each time and exposed to X-ray film (Kodak X-OMAT; Eastman Kodak, Rochester, NY) with an intensifying screen at Ϫ70°for 8-24 hr.
Statistical analysis. Data are given as mean Ϯ standard error. Differences were analyzed by t test and ANOVA, followed by the Bonferroni correction or Dunnett's test for multiple comparisons. Nonlinear regression analysis (InStat, GraphPAD Software, San Diego, CA) was used to determine the pK b for BMY 7378 and halfmaximal inhibitory concentrations for PD 98059. A value of p Ͻ 0.05 was considered significant. The values for n given in figure legends denote the number of independent experiments conducted on different cell lines and/or cell passages.
Results

Prolonged Activation of SMC ␣ 1 -ARs Increases Both Protein Synthesis and Protein Content
We previously reported that ␣ 1 -AR stimulation with NE for 24 hr increases the cellular content of ␣-actin mRNA and increases per-cell protein synthesis and content in a dosedependent (0.01-1 M) manner for aorta SMCs and intact aorta wall (7) . To examine the time dependence of this hypertrophy, growth-arrested SMCs were treated with 1 M NE for 8, 12, 24, and 48 hr. As shown in Fig. 1 , NE induced a progressive increase in protein synthesis, with a peak at 24 hr (170% of control) and then a decline to 130% at 48 hr. However, protein content per cell continued to increase (125% at 24 hr and 170% at 48 hr). In all NE-treated groups, cell number was not changed, and time-matched vehicletreated groups demonstrated no change in protein synthesis, content, or cell number (data not shown). These data for protein content at 24 and 48 hr points and protein synthesis at 24 hr are virtually identical to values we obtained previously in the presence of 0.5 M rauwolscine (7), demonstrating an absence of ␣ 2 -AR involvement. In additional experiments (n ϭ 4, data not shown) in which cells were exposed to 10 M NE, protein content per cell at 24 and 48 hr was 153 Ϯ 8 and 143 Ϯ 5, respectively, suggesting that together with the data of Fig. 1 , maximal hypertrophy is obtained at ϳ1 M NE for 48 hr of exposure.
Characterization of ␣ 1 -AR Subtype Mediating SMC Hypertrophy
Selective alkylation of ␣ 1B -ARs and protection of ␣ 1D -ARs with CEC in the presence of BMY 7378. The irreversible antagonist CEC is only 5-10-fold selective for ␣ 1B over the other ␣ 1 -ARs. This selectivity is critically dependent on CEC concentration, incubation time, and temperature; increasing any of these factors results in progressive alkylation of ␣ 1A -and ␣ 1D -ARs (23) . Therefore, results (7, 13, 17) obtained with CEC alone to differentiate among ␣ 1 -ARs may be inconclusive. We developed a "protection from alkylation" approach using CEC and the highly selective, competitive ␣ 1D -AR antagonist BMY 7378 (15) to identify which ␣ 1 -AR mediates SMC growth. To document the selectivity of BMY 7378 against ␣ 1 -AR-mediated growth, we first determined its potency against NE-induced protein synthesis in Rat-1 FBs stably transfected with one of the three different ␣ 1 -AR subtype cDNAs. In other experiments, we have used RPAs to confirm that only one of the cloned ␣ 1 -AR subtypes is expressed in each FB cell line. NE (24 hr) dose-dependently increased protein synthesis to similar degrees in all three FB cell lines that express different ␣ 1 -AR subtypes ( Fig. 2A) . The inhibitory effects of BMY 7378 on NE-induced (1 M, 24 hr) protein synthesis demonstrated the expected selectivity. As shown in Fig. 2B , BMY 7378 inhibited protein synthesis by ␣ 1D FBs in a dose-dependent pattern but had little effect against ␣ 1A or ␣ 1B FBs.
After establishing the selectivity of BMY 7378 against NE-induced protein synthesis, we then tested BMY 7378 for protection of ␣ 1D -ARs from CEC alkylation in an effort to increase the selectivity of CEC for ␣ 1B -AR inhibition. FBs were first incubated at 37°with 0.3 M BMY 7378 for 30 min. Preliminary experiments with different concentrations of BMY 7378 identified that 0.3 M afforded optimal selective protection from CEC. After extensive washing, cells were allowed to equilibrate at 37°for 30 min and then incubated with 1 M NE for 24 hr. , and 139 Ϯ 3% of control, respectively, in the absence of CEC and by 108 Ϯ 3%, 100 Ϯ 5%, and 98 Ϯ 6% after treatment with CEC (two or three independent experiments). These data demonstrate the absence of selectivity of CEC under the conditions that were used.
The above scheme for distinguishing among the ␣ 1D -and ␣ 1A /␣ 1B -ARs was then used to examine NE-induced protein synthesis in SMCs. To minimize BMY 7378 binding to ␣ 1B - 
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ARs in the subsequent SMC studies and because of the lower total ␣ 1 -AR expression in these cells, we used a 10-fold lower BMY 7378 concentration (0.3 M) that also gave the best selectivity ratios in FBs (see Discussion). As illustrated in Fig. 3 , the 160% increase in SMC protein synthesis induced by 1 M NE at 24 hr (second bar) was completely blocked by 0.3 M BMY 7378 (fourth bar). Furthermore, use of the same protocol for 0.3 M BMY 7378 protection from CEC alkylation as in Fig. 2 yielded a similar 60-70% protection of SMCs against CEC inhibition (third bar). Exposure to CEC alone for 30 min, without BMY 7378 protection of ␣ 1D -ARs, completely blocked the NE increase in protein synthesis (fifth bar). BMY 7378 and CEC, in the absence of NE stimulation, had no effect themselves on basal protein synthesis (sixth bar). We also used this protocol to examine the effect of BMY 7378 on protein synthesis induced by 1 M NE exposure for 48 hr and found the same complete inhibition by BMY 7378 of protein synthesis and 80% protection against CEC alkylation (two independent experiments; data not shown).
In other experiments using FBs and SMCs and the above protocols, 5-MU was also tested (0.03, 0.3, and 1 M). The concentration of 0.3 M 5-MU inhibited (by 50%) NE-induced protein synthesis by ␣ 1A -expressing FBs while having no effect on ␣ 1B -or ␣ 1D -FBs ( p Ͻ 0.05); the lower concentration was ineffective, and the higher concentration was nonselective. Moreover, 5-MU at these concentrations was ineffective in CEC protection experiments using FBs and yielded equivocal results in SMC protocols, which is consistent with its low selectivity between ␣ 1B -and ␣ 1D -ARs.
We also examined responses of passage 4-6 rat VC SMCs (five experiments from different cell lines or passages) because in our previous study (7), we saw no effect at 24 hr of 1 M NE on VC SMC growth. Exposure to 1 M NE for 48 hr, to test for a slower response time for VC SMC growth, still had no effect on protein synthesis (108 Ϯ 3% of time-matched control cells). However, in the presence of 0.3 M BMY 7378, NE now increased protein synthesis 30 Ϯ 5% ( p Ͻ 0.05). A similar increase (46 Ϯ 6%, p Ͻ 0.05) was also induced by NE after CEC treatment in the presence of 0.3 M 5-MU. NE plus 0.3 M 5-MU had no effect (100 Ϯ 10%), which is consistent with its absence of selectivity between ␣ 1B -and ␣ 1D -ARs. Because we also did not detect ␣ 1A -AR mRNA in RPAs of VC SMCs (see below), these data suggested that stimulation of ␣ 1B -and ␣ 1D -ARs on VC SMCs has different effects from those on aorta SMCs. Although differences in relative receptor densities between the two cell types may exist, these data suggest that in contrast to aorta SMCs, stimulation of ␣ 1D -ARs inhibits and stimulation of ␣ 1B -ARs induces protein synthesis by VC SMCs.
Equilibrium dissociation constant for BMY 7378 against NE-induced SMC growth. To further document the selectivity of BMY 7378 against ␣ 1 -AR mediated aorta SMC hypertrophy, we determined the apparent antagonist dissociation constant (K b ) of BMY 7378. BMY 7378 caused a rightward shift in the NE dose-response curve for SMC protein synthesis (Fig. 4) Fig. 3 indicate that ␣ 1D -ARs mediate aorta SMC hypertrophy.
Exposure of NE for 24 hr did not induce ␣ 1A -AR mRNA expression in SMCs. We have used RPAs to show that both ␣ 1D -and ␣ 1B -AR (not ␣ 1A -AR) transcripts and receptors are expressed in early passage rat SMCs cultured from aorta, VC, superior mesentery artery, pulmonary artery, and renal arterioles (7, 14) 1 and that exposure of rat aorta or VC SMCs to 1 M NE for 24 hr does not cause significant change in ␣ 1B -and ␣ 1D -AR mRNA levels (7). We tested whether prolonged exposure to NE induced ␣ 1A -AR mRNA expression, since induction of these receptors by NE (12) . However, as shown in Fig. 5 , ␣ 1A -AR mRNA was not detected by RPAs of a large amount of total RNA (Յ100 g) that was extracted from postconfluent, growth-arrested SMCs treated with NE for 24 and 48 hr. Expression of the cyclophilin gene was used as an internal assay control. Expression of ␣ 1A -AR mRNA by ␣ 1A FBs and submaxillary gland provided positive controls, and the absence of expression in liver and ␣ 2D -expressing cloned FBs served as negative controls. Identical results were obtained in a second independent experiment. These data demonstrate that the conclusion reached from the previous experiments that ␣ 1D -AR mediates aorta SMC growth was not complicated by the possible induction of ␣ 1A -AR expression during NE stimulation.
Time-and Dose-Dependent Protein Tyrosine Phosphorylation by NE
Tyrosine phosphorylation of cellular proteins is an immediate response after activation of certain receptor kinases and G protein-coupled receptors. To examine whether NE induces protein tyrosine phosphorylation in aorta SMCs, cell lysates from NE-treated or untreated SMCs were prepared and subject to immunoblot analysis with antiphosphotyrosine antibody. As showed in Fig. 6A , NE stimulated increase in a rapid, transient tyrosine phosphorylation of several proteins with apparent molecular masses of ϳ190, ϳ145, ϳ120, ϳ60 -90, and ϳ20 -55 kDa. Pretreatment with 0.3 M BMY 7378 blocked the increases in tyrosine phosphorylation, implicating the ␣ 1D -AR in this response. NE dose-dependently stimulated tyrosine phosphorylation of these proteins (Fig. 6B) . In addition, pretreatment with genistein (Calbiochem), a nonselective tyrosine kinase inhibitor, dose-dependently (0.3-50 M) inhibited NE-mediated protein tyrosine phosphorylation (data not shown). NE increased phosphorylation of a number of proteins with a similar time course, magnitude, and dose-sensitivity (Fig. 6 ). This likely relates to the expected large number of molecules involved in the contractile and growth pathways activated. Thus, similarities in time course and dose-sensitivity for many of the signals would not be unexpected. Other growth factors (e.g., thrombin, vasopressin, angiotensin II, endothelin) have been shown (36 -39) to have similar effects in these and other cells. Proteins that lacked basal phosphorylation that could be detected by this assay under control conditions were not phosphorylated by NE. There were some exceptions to the molpharm.aspetjournals.org aforementioned similarities. As shown in Fig. 6B , the peak response for the 200-kDa band was obtained at a lower NE concentration than for most of the other proteins. NE did not induce additional phosphorylation above control levels for some proteins, especially those between 28 and 65 kDa. Also, not all bands changed intensity with identical time courses (Fig. 6A) . For example, the proteins around 28 kDa increase intensity later and decline more quickly. The proteins at 28 and 30 kDa returned to base-line by 60 min, which is in contrast to the 69-and 110-kDa protein clusters.
Role of MAPK Pathway in ␣ 1D -AR Mediated SMC Hypertrophy
␣ 1D -AR stimulation activates MAPK. MAPKs are a family of serine/threonine kinases of 42 and 44 kDa that are activated by phosphorylation of specific tyrosine and threonine residues. MAPKs are thought to serve as a convergence point for diverse signaling pathways used by a variety of growth stimuli. To begin to investigate the intracellular pathways through which NE induces growth of aorta SMCs, we tested whether NE activates MAPK. Activation of MAPK was assayed by Western detection of the appearance of their phosphorylated forms, which show reduced mobility in SDSpolyacrylamide gels, and by a direct in vitro kinase assay of MAPK immunoprecipitatable activity using myelin basic protein as the substrate. As shown in Fig. 7A , both assays revealed that 1 M NE caused rapid and time-dependent activation of MAPK (peaked at 10 min), followed by a decline to basal level over a 120-min exposure to NE. When assayed after 10 min of NE stimulation, NE activated MAPK, with the maximal response achieved at the same concentration (1 M NE, Fig. 7B ) that produced maximal activation of protein synthesis and accumulation (see above). These MAPK data also agree in time and NE sensitivity with the pattern of overall tyrosine phosphorylation (Fig. 6 ). However, due to lower abundance, p42-p44 MAPKs were not detected with the short film exposure required for the antiphosphotyrosine antibody immunoblot assays (Fig. 6) .
To test whether activation of MAPK is through stimulation of ␣ 1D -ARs, we used the same "protection from alkylation" method as applied to the protein synthesis experiments (Figs. 2 and 3) , except that SMCs were exposed to 1 M NE for only 10 min in this experiment. In full agreement with induction of SMC protein synthesis (Fig. 3) , 0.3 M BMY 7378 or 30 M CEC alone completely inhibited activation of MAPK by NE (Fig. 7C, fourth and fifth bars) . Likewise, protection of ␣ 1D -ARs by BMY 7378 during exposure to CEC again protected 85% of the MAPK activation from inhibition by CEC (Fig. 7C, third bar) . In comparison to the control group, BMY 7378 plus CEC treatment alone had no effect on basal MAPK activity (Fig. 7C, first and sixth bars) . These data demonstrate that ␣ 1D -AR-mediated aorta SMC protein synthesis is associated with activation of the p42-p44 MAPK pathway. Raf-1 is a ubiquitous serine kinase implicated in the signaling cascade upstream to MAPK activation. Activation of Raf-1 kinase is dependent on phosphorylation of multiple serine and threonine residues, which results in retardation of its migration in SDS-polyacrylamide gels. To determine whether ␣ 1D -AR stimulation activates Raf-1, aorta SMCs were incubated with 1 M NE for various times, and cell lysates containing equal amounts of protein were subjected to immunoblot analysis using antiRaf-1 polyclonal and monoclonal antibodies. Both antibodies gave similar results. NE caused a time-dependent mobility retardation of Raf-1 to a 74-kDa band compared with the 70-kDa band characteristic of unstimulated Raf-1 (Fig. 8) . Raf-1 phosphorylation was sustained for Ն2 hr (data not shown). Treatment of cells with EGF for 10 min served as a positive control. Pretreatment with 0.3 M BMY 7378 for 30 min followed by 1 M NE for 10 min inhibited retardation of Raf-1 mobility. The PKC inhibitor calphostin C (Calbiochem) (100 nM) partially blocked NE activation of Raf-1 (Fig. 8) . These data indicated that ␣ 1D -AR stimulation of rat aorta SMCs induces rapid and sustained Raf-1 phosphorylation that may involve PKC.
␣ 1D -AR stimulation induces expression of c-fos mRNA. Activation of MAPK has been linked to transactivation of various growth-promoting genes, including the c-fos proto-oncogene in a variety of cell types, which is partially dependent on tyrosine kinase stimulation (26) . We used Northern analysis to test for activation of this distal target in the MAPK pathway. Fig. 9 shows that exposure of aorta SMCs to 1 M NE induced time-dependent (30 and 60 min) c-fos mRNA expression. Induction was blocked by pretreatment with either 0.3 M BMY 7378 or 20 M tyrphostin (inhibitor of tyrosine phosphorylation) (Calbiochem). As with Raf-1 activation (Fig. 8) , calphostin C partially blocked c-fos expression (not shown). These observations strengthen the conclusion that NE-stimulated protein synthesis in rat aorta SMCs is coupled through the ␣ 1D -AR to activation of the MAPK cascade. Unlike the data shown in Fig. 9 , in the other two replicates of this experiment, GAPDH did not consistently increase with NE or decrease with BMY 7378 or tyrphostin; this is in agreement with the absence of effect of NE on cyclophilin message (Fig. 5 ).
MEK inhibition with PD 98059 blocks NE-induced protein synthesis and MAPK activation of SMCs.
To determine whether activation of the p42-p44 MAPK cascade is required for ␣ 1D -AR-induced SMC hypertrophy, aorta SMCs were treated with various concentrations of PD 98059 (0.01-30 M), a selective MEK inhibitor (27, 28) , or the vehicle Me 2 SO (final concentration 0.1%) in the presence of 1 M NE for 24 hr. As shown in Fig. 10A , PD 98059 dose-dependently inhibited NE-induced protein synthesis. Inhibition extended over an expected 100-500-fold range of PD 98059, with half-maximal inhibition obtained at ϳ2.3 M. However, PD 98059 did not completely inhibit protein synthesis, even at 30 M. In contrast, both 10 and 30 M genistein completely inhibited NE induction of protein synthesis (data not shown). The selectivity of PD 98059 on MAPK was verified by gel shift and immunocomplex in vitro kinase assays. NE activation (1 M, 10 min) of MAPK was dose-dependently inhibited by PD 98059 with half-maximal inhibition at 1.6 M (Fig.  10B) . Furthermore, 0.01-30 M PD 98059 had no effect on NE (1 M, 10 min)-induced increase in tyrosine phosphorylation of the SMCs cellular proteins identified in the Western blot assay using antiphosphotyrosine antibody (data not shown). In several preliminary experiments, PD 98059, as examined over the full concentration range shown in Fig. 10 , had no effect on basal MAPK activity. These data clearly demonstrate the selectivity of PD 98059 at the concentrations used and show that activation of MAPK is required for ␣ 1D -AR-induced protein synthesis in SMCs.
Discussion
The subtype or subtypes mediating ␣ 1 -AR growth of aorta SMCs (7, 8) and the signaling pathway have not been identified, in part because SMCs (depending on vessel of origin) can express all three subtypes and because sufficiently selective antagonists, especially for the ␣ 1B -ARs, are lacking. SMCs in the intact rat aorta medial layer, which is composed entirely of SMCs (see Refs. 7 and references therein) express ␣ 1D -and ␣ 1B -ARs (7, 14) . It is not clear whether in vivo aorta SMCs also express ␣ 1A -ARs because previous reports of the presence of this transcript have been for whole aorta and did not distinguish between FB RNA in the adventitial layer Fig. 8 . NE stimulates rapid and sustained phosphorylation of Raf-1. Aorta SMCs were treated with 1 M NE or EGF for indicated time periods. The cell lysates (100 g) were subjected to 12% SDS-polyacrylamide gels and Western blotting with anti-Raf antibody. Cells were exposed to BMY 7378 or calphostin C (CPC) 30 min before a 10-min exposure to NE. Data are representative of three independent experiments. Raf-1 remained shifted in cells exposed to NE for Ն2 hr (data not shown). which comprise approximately one third of the aorta wall mass. In vivo studies are required to confirm the current results and determine whether there is a role for ␣ 1A -ARs in SMC growth in vivo. In the current study, we found that early passage rat aorta SMCs do not express ␣ 1A -AR mRNA detectable by RPAs, nor is expression induced by prolonged exposure to NE. Previously, we demonstrated in cultured rat aorta SMCs the presence of mRNAs for ␣ 1D -and ␣ 1B -ARs (7, 14) and the presence of CEC-sensitive and -insensitive ␣ 1 -AR binding sites (presumably ␣ 1B -and ␣ 1D -ARs) using conditions that favor CEC selectivity in radioligand binding assays (14) . Thus, the absence of ␣ 1A -ARs simplified the pharmacological strategy required to distinguish between ␣ 1B -and ␣ 1D -ARs for induction of aorta SMC protein synthesis.
We used BMY alone and to protect ␣ 1D -ARs during concomitant incubation with CEC as a means of increasing CEC selectivity for ␣ 1B -ARs. The validity of this "protection from alkylation" strategy was initially documented using Rat-1 FB cell lines that each express one of the three cloned ␣ 1 -AR subtypes. Stimulation of each subtype with NE induced a similar dose-dependent increase in protein synthesis. This demonstrates that each AR subtype can couple to growthpromoting pathways in these cloned FBs. However, total ␣ 1 -AR density in native vascular SMCs in situ or in culture (ϳ20 fmol/mg of protein for aorta SMCs) (14) is Ն100-fold lower than for these FBs. Because of potential coupling promiscuity in cells overexpressing transfected receptors, these growth responses in FB cell lines cannot be used to predict that any ␣ 1 -AR subtype natively expressed by SMCs can induce hypertrophy when stimulated. For example, all three ␣ 1 -ARs when overexpressed couple to the same phospholipase C effector system (29) and similarly down-regulate to agonist in Rat-1 FBs (30). However, agonist exposure has a differential effect on down-regulation of ␣ 1 -AR mRNAs in aorta SMCs that express native ␣ 1B -and ␣ 1D -ARs (7) and in neonatal cardiac myocytes that natively express all three subtypes (12) . Also, the endogenous ␣ 1A -AR seems to mediate the hypertrophic program in rat cardiac myocytes (12, 31) , but overexpression of a constituitively active ␣ 1B -AR mutant in mouse heart can also induce hypertrophy (32) .
In agreement with previous studies concerning its relative selectivity (15, 24, 25) , 3 M BMY 7378 inhibited FB protein synthesis induced by ␣ 1D -, ␣ 1A -, and ␣ 1B -ARs by 75%, 23%, and 5%, respectively, and a similar selectivity for protection from CEC inhibition was obtained (Fig. 2) . To minimize BMY 7378 binding to ␣ 1B -ARs in the subsequent SMC studies and because of the lower total ␣ 1 -AR expression in these cells, we used a 10-fold lower BMY 7378 concentration (0.3 M) that also gave the best selectivity ratios in FBs. As expected, in ␣ 1D -AR FBs, this concentration did not provide complete blockade of NE-induced protein synthesis (50% inhibition) and protection from CEC (69%) (Fig. 2) . However, perhaps due to the lower density of ␣ 1 -ARs on SMCs, 0.3 M BMY 7378 completely inhibited the increase in SMC protein synthesis by NE and provided a 65% protection of the response from inhibition by CEC (Fig. 3) . The partial inhibition by CEC during BMY 7378 protection likely reflects some alkylation of ␣ 1D -ARs. This is consistent with the lack of selectivity of CEC when used without protection of non-␣ 1B -ARs; CEC alone completely abolished protein synthesis in all three FB cell lines and in SMCs. Overall, these data suggest that ␣ 1D -ARs on rat aorta SMCs, which comprise ϳ70 -80% of the total ␣ 1 -AR population, with the remaining being ␣ 1B -ARs (14) , mediate adrenergic hypertrophy. Although a small ␣ 1B -AR contribution cannot be directly ruled out, confirmation of the role of ␣ 1D -ARs was provided by the pK b value obtained with 0.3 M BMY 7378 against NE-induced protein synthesis in aorta SMCs (8.4) , which compares well with K i values reported by others for BMY 7378 (15, 24, 25) . And importantly, 0.3 M BMY 7378 completely blocked NE-stimulated SMC protein synthesis, tyrosine phosphorylation, activation of MAPK, Raf-1, and expression of c-fos mRNA.
Incubation of SMCs or cloned FBs with 30 M CEC for 30 min, followed by extensive washing, completely eliminated increases in protein synthesis during subsequent exposure to NE for Յ48 hr. This suggests that there may be little or no receptor reserve for ␣ 1D -AR-mediated SMC growth and that Ͼ 48 hr are required for sufficient replacement of alkylated ␣ 1 -ARs, which is consistent with a relatively slow restoration of ␣ 1 -ARs after alkylation (33, 34) . For example, ␣ 1 -AR density in rat aorta SMCs, which was decreased by 83% after a 30-min treatment with 1 M phenoxybenzamine, remained decreased by 53% 24 hr later (34) . It is also possible that after alkylation with CEC, continuous exposure to NE may further slow replacement of functional receptors due to agonist-induced receptor down-regulation. Thus, in the current study, when ␣ 1B -ARs were selectively removed and ␣ 1D -ARs were preserved by incubation of SMCs with CEC in the presence of BMY 7378, partial restoration of ␣ 1B -ARs may have occurred during the interval before measurement of protein synthesis at 24 and 48 hr. However, the findings that BMY 7378 afforded ϳ80% preservation of NE induction of protein synthesis at both 24 and 48 hr and a similar 85% protection of MAPK activation when measured within only 1 hr after CEC treatment lend further support to the conclusion that the ␣ 1D -AR, and not the ␣ 1B -AR, mediates SMC catecholamine hypertrophy.
Protein tyrosine phosphorylation is an essential component in signaling cell growth and mitogenesis (35) . The pattern of genistein-sensitive, increased tyrosine phosphorylation produced by ␣ 1D -AR stimulation with NE (Fig. 6 ) seems to exhibit bands both common to and different from other agonists acting on aortic SMCs as reported by others (36 -39) , although comparisons within the same assay will be needed for confirmation. Comparative immunolabeling studies are also required using antibodies that have identified proteins phosphorylated by vasoactive and growth-or mitogenesisassociated peptides like PDGF-BB and thrombin (36) , vasopressin (37), angiotensin II (38) , and endothelin (39); these include phospholipase C-␥ (145 kDa), p21 ras GAP (125 kDa), p125 fak , PI3 kinase ␣ subunit (85 kDa), paxillin (76 kDa), caldesmon (70 kDa), p60 v-src , p56
shc , and p46 shc . Such studies are needed to begin to identify common and unique proteins activated by ␣ 1D -ARs.
Like many growth factors, NE induced dose-dependent, transient protein tyrosine and MAPK phosphorylation but relatively sustained Raf-1 and c-fos activation. The demonstration of NE-elicited Raf-1 phosphorylation (Fig. 8 ) differs from that produced by EGF in that the intensity of the lower-molecular-weight species does not seem to decline with NE stimulation. However, like EGF, NE clearly leads to hyperphosphorylation and the expected gel retardation of Raf-1. The use of BMY 7378 and CEC in these assays demonstrated their coupling to ␣ 1D -ARs. Sustained activation of Raf-1 kinase is consistent with Raf-1 autophosphorylation, which prevents rapid inactivation after release of Ras binding (40) . There is evidence that transient rather than sustained activation of MAPK may be a critical determinant of whether certain cells responds with growth or with differentiation (19) . Activation of Raf-1 was partially inhibited by the PKC inhibitor calphostin C. Previous studies have demonstrated the activation of c-fos by NE in rat aorta SMCs (13, 41) . The nonspecific tyrosine kinase inhibitors genistein and tyrphostin inhibited protein tyrosine phosphorylation and abolished c-fos increase. Although additional studies are required to confirm these findings, they suggest that ␣ 1D -AR stimulation activates both a PKC-dependent and -independent pathway (19) . Recent evidence suggests that some G protein-coupled receptors can activate MAPK through both G ␣ /PKC/Raf-1-and G ␤␥ /Ras/Raf-1-dependent pathways (18) . The requirement of tyrosine phosphorylation for ␣ 1D -AR hypertrophy was suggested by blockade of NE increases in protein synthesis by 10 M genistein, which also abolished MAPK activation.
Activation of p42-p44 MAPKs is mediated by phosphorylation of tyrosine and threonine residues by MEK, which is dependent on serine phosphorylation by Raf-1 and possibly by other MEKs (18, 42) . There is evidence that ␣ 1 -AR stimulation of rat aorta SMCs activates membrane-bound Ras GTPase (43) , which is activated by multiple effectors other than G ␤␥ and has multiple downstream targets, including Raf-1 (19) . Interestingly, ␣ 1 -AR stimulation of aorta SMCs induces coimmunoprecipitation of Ras and PI3 kinase, and the PI3 kinase inhibitor wortmannin reduces NE increases in DNA synthesis (44) . Thus, G ␤␥ activation of PI3 kinase may provide an additional pathway to Ras activation (19, 40, 43, 44) , on which ␣ 1D -AR SMC hypertrophy may depend. It also remains possible that ␣ 1D -AR increases in protein synthesis involve an autocrine growth factor mechanism. Majeski et al. (41) demonstrated that constant arterial infusion of phenylephrine or NE over 48 hr (but not endothelin or angiotensin II, which causes similar hypertension) produced 10-fold increase in PDGF-A mRNA in rat aorta but not other tissues examined.
The MEK inhibitor PD 98059 produced dose-dependent (0.1-10 M) complete inhibition of MAPK activation and maximal 80% inhibition of the increase in protein synthesis produced by ␣ 1D -AR stimulation (Fig. 10) . However, PD 98059 had no effect on the pattern of increased tyrosine phosphorylation evident in Fig. 6 . These data suggest that MAPK activation is required for the majority of ␣ 1D -AR hypertrophy of SMCs. However, although the dose-sensitivity and -specificity we demonstrated for PD 98059 are in agreement with the results of others (27, 28) , this conclusion relies on an indirect demonstration of MEK requirement. Interestingly, the PD 98059 data identified a residual MAPK-independent component of the ␣ 1D -AR increase in protein synthesis. Additional studies will be required to determine whether this component depends on G protein activation of an additional pathway.
Similar pathways demonstrated in the current study for ␣ 1D -AR-mediated SMC hypertrophy may underlie NE-induced SMC proliferation produced by competent vascular SMCs (Ref. 6 and references therein; Ref. 8) . In a recent report (17) , ␣ 1 -AR stimulation of subconfluent passage 5-15 rat aorta SMC induced a 3-fold maximal increase in DNA synthesis (EC 50 ϳ 1 nM). This increase, which was first evident at 12 hr (but not at 8 hr, as in the current study), was accompanied by a 60% increase in cell number over 6 days of stimulation that was comparable to that produced by PDGF and endothelin. Interestingly, increases in MAPK activity reported in that study were similar in magnitude and time course to those that we report. However, as in other previous studies (7, 8) , the use of CEC alone by Yu et al. (17) , which abolished the responses, prevented identification of the responsible ␣ 1 -AR subtype, and no causal relationship was established between MAPK activation and SMC proliferation. Nevertheless, these data and those from the current study suggest that catecholamines may activate a similar signaling cascade for proliferation and hypertrophy. Several points are noteworthy regarding the potential physiological significance of our results. Pathways activated by both contraction and growth induced by NE as well as other stimuli (e.g., vasopressin, angiotensin II, PDGF, thrombin, endothelin, EGF) and receptor-independent depolarization (45) seem to share many similarities, including activation of the MAPK cascade formerly believed to be induced only by trophic stimuli (46) . It is possible that coactivation of a parallel growth-promoting pathway by SMC contraction, which may result in minimal if any trophic changes during short-term contraction, could serve to initiate vascular wall thickening should activation of the trophic pathway be sustained. Coupling of a prolonged contractile stimulus to SMC growth could result in several outcomes. Depending on the amount of increase in lumen pressure and change in lumen diameter, structural increases in wall thickness could favor restoration of normal wall stress. SMC hypertrophy could also increase the mechanical advantage of the vascular wall and amplify the contractile potency and efficacy of the agonist. This could serve to maintain agonist reactivity despite receptor desensitization, an effect that might have both normal adaptive but also potential pathological consequences in vascular disease.
